100367-40-6 Usage
Description
2-Amino-5-bromo-4-methyl-3-nitropyridine is a chemical compound characterized by the molecular formula C6H6BrN3O2. It is a yellow solid with a molecular weight of 216.03 g/mol. 2-Amino-5-bromo-4-methyl-3-nitropyridine is recognized for its functional groups, including an amino group, a nitro group, and a bromine atom, which contribute to its reactivity and versatility in chemical synthesis. Its structure and properties render it a valuable intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds, while also exhibiting antimicrobial and anti-inflammatory properties, indicating its potential in drug development.
Uses
Used in Pharmaceutical Industry:
2-Amino-5-bromo-4-methyl-3-nitropyridine is used as a synthetic intermediate for the development of various pharmaceuticals. Its unique combination of functional groups facilitates its incorporation into a wide range of medicinal compounds, enhancing their therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Amino-5-bromo-4-methyl-3-nitropyridine serves as a key intermediate in the synthesis of agrochemicals. Its chemical reactivity allows for the creation of compounds with pesticidal or herbicidal properties, contributing to crop protection and yield enhancement.
Used in Organic Synthesis:
2-Amino-5-bromo-4-methyl-3-nitropyridine is utilized as a versatile building block in organic synthesis. Its presence in various chemical reactions enables the formation of a broad spectrum of organic compounds, expanding the scope of chemical research and development.
Used in Drug Development:
Due to its antimicrobial and anti-inflammatory properties, 2-Amino-5-bromo-4-methyl-3-nitropyridine is employed in the development of new drugs. Its potential to combat infections and reduce inflammation positions it as a promising candidate for pharmaceutical innovation.
Each application underscores the compound's multifaceted utility, reflecting its importance across different scientific and industrial domains.
Check Digit Verification of cas no
The CAS Registry Mumber 100367-40-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,3,6 and 7 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 100367-40:
(8*1)+(7*0)+(6*0)+(5*3)+(4*6)+(3*7)+(2*4)+(1*0)=76
76 % 10 = 6
So 100367-40-6 is a valid CAS Registry Number.
InChI:InChI=1/C6H6BrN3O2/c1-3-4(7)2-9-6(8)5(3)10(11)12/h2H,1H3,(H2,8,9)
100367-40-6Relevant articles and documents
An alternate route to 2-amino-3-nitro-5-bromo-4-picoline: Regioselective pyridine synthesis via 2-nitramino-picoline intermediate
Bhattacharya, Apurba,Purohit, Vikram C.,Deshpande, Prashant,Pullockaran, Annie,Grosso, John A.,DiMarco, John D.,Gougoutas, Jack Z.
, p. 885 - 888 (2007)
The 2-nitramino functionality in 2-nitramino-4-picoline was successfully exploited not only as a protecting group but also as a directional handle to afford an efficient, atom-economic, and regioselective synthesis of 2-amino-5-bromo-3-nitro-4-picoline (4), a precursor for a drug candidate in development.
QUINOXALINE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR
-
Page/Page column 33-34, (2021/07/24)
The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
Preparation of the HIV Attachment Inhibitor BMS-663068. Part 1. Evolution of Enabling Strategies
Fox, Richard J.,Tripp, Jonathan C.,Schultz, Mitchell J.,Payack, Joseph F.,Fanfair, Dayne D.,Mudryk, Boguslaw M.,Murugesan, Saravanababu,Chen, Chung-Pin H.,La Cruz, Thomas E.,Ivy, Sabrina E.,Broxer, Sévrine,Cullen, Ryan,Erdemir, Deniz,Geng, Peng,Xu, Zhongmin,Fritz, Alan,Doubleday, Wendel W.,Conlon, David A.
, p. 1095 - 1109 (2017/08/23)
The development of two enabling routes that led to the production of >1000 kg of BMS-663068 (3) is described. The route identified for the initial 100 kg delivery to support development activities and initial clinical trials involved the conversion of 2-amino-4-picoline to the parent active pharmaceutical ingredient (API), followed by pro-drug installation and deprotection. To eliminate the problematic isolation of the parent API and synthesis of di-t-butyl(chloromethyl)phosphate, a second-generation pro-drug installation route was developed which involved the conversion of a late-stage common intermediate to an N(1)-thioether derivative followed by chloromethylation, displacement with di-t-butylpotassium phosphate, and deprotection. This second strategy resulted in the multikilogram scale preparation of the API in 14 linear steps and ～7% overall yield.
